



Supplementary Figure 1


a






b



c



d



Supplementary Fig. 1. HS derives lysosomal dysfunction that can be prevented by MA-5, but not spiro.

(a) Principal component analysis scatter plot in RNA sequencing with MDCTs treated with HS or HS+Aldo in the presence or absence of MA-5 or Spiro. (b) KEGG enrichment analysis in the RNaseq of MDCTs treated with HS or HS+MA-5. (c) KEGG enrichment analysis in the RNaseq of MDCTs treated with HS+Aldo in the presence or absence of MA-5. (d) Volcano blots in RNA sequencing with MDCTs treated with HS or HS+Aldo in the presence or absence of MA-5 or Spiro. HS, high salt; Spiro, spironolactone; FDR, false discovery rate.